ED Treatment Pills in AI Search: The Biggest AI Visibility Problems and How We'd Fix Them

Companies covered: Ro, Hims, Optum, Rex MD, BlueChew, K Health, plushcare, GoodRx Care, Blink Health, Lemonaid Health

Answer Capsule

The November 2026 ED Treatment Pills benchmark compares 10 companies across 281 AI answers that met its inclusion rules. Hims recorded 252 mentions and 189 recommendations (67.26% of the answers). Being mentioned means appearing in an answer; being recommended means receiving an affirmative endorsement.

We examine each company, compare the available monthly results, and set out a five-step plan for improving the information AI systems can draw on. The work starts with measuring visibility and checking conflicting claims, then moves to company pages, relevant publishers and buyer questions. The cited pages need review before any correction request, and the research does not establish what caused recommendation differences or promise future gains.

Executive industry diagnosis

Questions This Section Answers

• What does the ED Treatment Pills benchmark show about mentions, recommendations and placement?

The peer set splits into a clear leading group and a long tail. Hims, Ro and GoodRx Care appear in most answers and are recommended in a large share of them, so they set the frame other brands are judged against. The gap between that group and the rest is the defining feature of this market.

Mid-tier brands such as plushcare and Lemonaid Health are mentioned often but recommended less consistently, which suggests they are familiar names rather than default picks. Lower-ranked brands appear in fewer answers and are rarely endorsed, so their visibility is thin even where sentiment is positive.

For a client in this space, the practical question is whether to defend a leading position or build recognition from the tail. We would start by mapping where the client sits against these tiers, then focus effort on the questions where its absence or weak endorsement is most costly.

What changed since last month

Questions This Section Answers

• What changed across the usable monthly ED Treatment Pills snapshots?

Only months with verified results are shown. Monthly sample coverage is listed in Methodology.

Several companies moved between the two selected months, but the samples differ, so these are separate snapshots rather than a like-for-like trend. Optum and K Health recorded more mentions and recommendations in the later sample, while Lemonaid Health and BlueChew recorded fewer recommendations.

Hims and Ro both recorded more recommendations alongside fewer mentions, and plushcare recorded gains on both measures. Because the answer sets are not identical, we treat these as observed movements only. We would document the cohort and collection conditions before drawing any conclusion about direction.

Company-by-company findings

Ro

Questions This Section Answers

• What measured visibility pattern and review priority does Ro have in ED Treatment Pills?

Ro recorded 237 mentions (84.34%) and 179 recommendations (63.70%) across 281 answers included in the benchmark. Top 3 placements numbered 131; first-place recommendations numbered 20. Framing among its mentions was 180 positive, 54 neutral and 3 negative.

From October 2026 to November 2026, Ro's mention count fell from 244 to 237, while its recommendation count rose from 163 to 179. The recommendation rate was 55.07% and 63.70% respectively.

AI answers contained 0 conflicting claims about Ro: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Another 1 possible conflicts were excluded because the company match was uncertain. They need an identity check before substantive review.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://ro.co/erectile-dysfunction/viagra-prescription/.

Selected third-party review candidate: https://goodrx.com/sildenafil/viagra-now-available-directly-online.

Ro combines broad reach with a strong recommendation share, yet first-place finishes are comparatively rare. That pattern points to a brand that is routinely endorsed as a solid option without being named the single best. We would review the supplied owned and third-party pages against current primary sources before proposing any edit, and treat the recommendation gap as a framing question to investigate rather than a conclusion.

Hims

Questions This Section Answers

• What measured visibility pattern and review priority does Hims have in ED Treatment Pills?

Hims recorded 252 mentions (89.68%) and 189 recommendations (67.26%) across 281 answers included in the benchmark. Top 3 placements numbered 144; first-place recommendations numbered 75. Framing among its mentions was 192 positive, 57 neutral and 3 negative.

From October 2026 to November 2026, Hims' mention count fell from 274 to 252, while its recommendation count rose from 180 to 189. The recommendation rate was 60.81% and 67.26% respectively.

AI answers contained 6 conflicting claims about Hims: 0 critical, 1 high, 5 medium, 0 low. Of these, 1 was rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://hims.com/erectile-dysfunction/sildenafil.

Selected third-party review candidate: https://innerbody.com/bluechew-vs-hims.

Hims leads the peer set on reach and recommendations, and its first-place count is the highest recorded. The disputed claims logged against it concern pricing, which is exactly the kind of detail buyers check before choosing. We would verify those figures against current primary sources, then prepare a page brief that states pricing clearly and consistently so answers have a reliable basis to quote.

Optum

Questions This Section Answers

• What measured visibility pattern and review priority does Optum have in ED Treatment Pills?

Optum recorded 22 mentions (7.83%) and 17 recommendations (6.05%) across 281 answers included in the benchmark. Top 3 placements numbered 14; first-place recommendations numbered 7. Framing among its mentions was 17 positive, 5 neutral and 0 negative.

From October 2026 to November 2026, Optum's mention count rose from 13 to 22, while its recommendation count rose from 2 to 17. The recommendation rate was 0.68% and 6.05% respectively.

AI answers contained 0 conflicting claims about Optum: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://perks.optum.com/blog/how-to-get-finasteride.

Selected third-party review candidate: https://optumrx.com/en/.

Optum's recorded presence grew in the later sample, with recommendations rising alongside mentions. The base is still small, so this is an early signal rather than an established position. We would check whether the supplied pages describe Optum's offer in terms buyers use, and prepare a brief only after confirming current details with primary sources.

Rex MD

Questions This Section Answers

• What measured visibility pattern and review priority does Rex MD have in ED Treatment Pills?

Rex MD recorded 51 mentions (18.15%) and 33 recommendations (11.74%) across 281 answers included in the benchmark. Top 3 placements numbered 17; first-place recommendations numbered 1. Framing among its mentions was 33 positive, 16 neutral and 2 negative.

From October 2026 to November 2026, Rex MD's mention count rose from 43 to 51, while its recommendation count rose from 26 to 33. The recommendation rate was 8.78% and 11.74% respectively.

AI answers contained 0 conflicting claims about Rex MD: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://rexmd.com/.

Selected third-party review candidate: https://goodrx.com/sildenafil/viagra-now-available-directly-online.

Rex MD is mentioned in a modest share of answers but recommended in most of those mentions, which suggests a brand that earns endorsement when it appears. First-place finishes are rare, so the opportunity is depth of presence rather than stronger wording. We would review the supplied pages for clarity on offer and eligibility, verifying facts first, and brief content around the questions where the brand already appears.

BlueChew

Questions This Section Answers

• What measured visibility pattern and review priority does BlueChew have in ED Treatment Pills?

BlueChew recorded 68 mentions (24.20%) and 33 recommendations (11.74%) across 281 answers included in the benchmark. Top 3 placements numbered 16; first-place recommendations numbered 2. Framing among its mentions was 34 positive, 31 neutral and 3 negative.

From October 2026 to November 2026, BlueChew's mention count rose from 64 to 68, while its recommendation count fell from 38 to 33. The recommendation rate was 12.84% and 11.74% respectively.

AI answers contained 16 conflicting claims about BlueChew: 3 critical, 1 high, 12 medium, 0 low. Of these, 4 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://bluechew.com/blogs/medication/bluechew-vs-hims.

Selected third-party review candidate: https://medicalnewstoday.com/articles/bluechew-vs-hims.

BlueChew carries the heaviest fact-checking load in this peer set, with several disputed claims rated high or critical, including whether a free trial exists. Those conflicts matter because trial and price details shape buyer decisions. We would resolve each claim against current primary sources before any correction, keep uncertain matches out of the queue, and only then brief page updates that state the offer plainly.

K Health

Questions This Section Answers

• What measured visibility pattern and review priority does K Health have in ED Treatment Pills?

K Health recorded 17 mentions (6.05%) and 15 recommendations (5.34%) across 281 answers included in the benchmark. Top 3 placements numbered 5; first-place recommendations numbered 1. Framing among its mentions was 16 positive, 1 neutral and 0 negative.

From October 2026 to November 2026, K Health's mention count rose from 9 to 17, while its recommendation count rose from 7 to 15. The recommendation rate was 2.36% and 5.34% respectively.

AI answers contained 0 conflicting claims about K Health: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://khealth.com/uti.

Selected third-party review candidate: https://goodrx.com/healthcare-access/telehealth/popular-telehealth-apps.

K Health's recorded mentions and recommendations both rose in the later sample, though from a small base. Sentiment is almost entirely positive, so the constraint is presence rather than perception. We would examine the supplied pages for whether they answer common telehealth questions directly, verify current facts, and brief content that gives answers a clear reason to include the brand.

plushcare

Questions This Section Answers

• What measured visibility pattern and review priority does plushcare have in ED Treatment Pills?

plushcare recorded 111 mentions (39.50%) and 92 recommendations (32.74%) across 281 answers included in the benchmark. Top 3 placements numbered 40; first-place recommendations numbered 6. Framing among its mentions was 92 positive, 18 neutral and 1 negative.

From October 2026 to November 2026, plushcare's mention count rose from 91 to 111, while its recommendation count rose from 68 to 92. The recommendation rate was 22.97% and 32.74% respectively.

AI answers contained 0 conflicting claims about plushcare: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://plushcare.com/viagra-sildenafil-prescription.

Selected third-party review candidate: https://goodrx.com/healthcare-access/telehealth/popular-telehealth-apps.

plushcare records substantial reach and a healthy recommendation share, but first-place finishes are limited relative to its overall presence. That suggests a familiar, well-regarded option that rarely tops a list. We would review the supplied pages for the specific services and conditions buyers ask about, confirm details with primary sources, and brief content that strengthens the case for a leading position.

GoodRx Care

Questions This Section Answers

• What measured visibility pattern and review priority does GoodRx Care have in ED Treatment Pills?

GoodRx Care recorded 214 mentions (76.16%) and 168 recommendations (59.79%) across 281 answers included in the benchmark. Top 3 placements numbered 122; first-place recommendations numbered 62. Framing among its mentions was 171 positive, 43 neutral and 0 negative.

From October 2026 to November 2026, GoodRx Care's mention count rose from 207 to 214, while its recommendation count rose from 151 to 168. The recommendation rate was 51.01% and 59.79% respectively.

AI answers contained 1 conflicting claim about GoodRx Care: 0 critical, 0 high, 1 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://goodrx.com/sildenafil/viagra-now-available-directly-online.

Selected third-party review candidate: https://verold.com/best-telehealth-services-primary-care-mental-health-2026/.

GoodRx Care sits in the leading group on both reach and recommendations, with no negative framing recorded. One disputed claim concerns visit pricing, a detail buyers weigh heavily. We would verify the current price structure against primary sources, then prepare a page brief that presents pricing in a form answers can quote accurately and consistently.

Blink Health

Questions This Section Answers

• What measured visibility pattern and review priority does Blink Health have in ED Treatment Pills?

Blink Health recorded 20 mentions (7.12%) and 20 recommendations (7.12%) across 281 answers included in the benchmark. Top 3 placements numbered 12; first-place recommendations numbered 5. Framing among its mentions was 20 positive, 0 neutral and 0 negative.

From October 2026 to November 2026, Blink Health's mention count stayed at 20, while its recommendation count rose from 15 to 20. The recommendation rate was 5.07% and 7.12% respectively.

AI answers contained 0 conflicting claims about Blink Health: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://blinkhealth.com/tadalafil.

Selected third-party review candidate: https://clearwayhealth.com/post/these-online-pharmacies-can-make-getting-your-prescription-so-much-easier.

Blink Health appears in a small share of answers but is recommended whenever it does, and its framing is entirely positive. The constraint is how often it surfaces, not how it is described. We would review the supplied pages for whether they clearly explain the service and its savings model, verify current facts, and brief content around the prescription questions where the brand already appears.

Lemonaid Health

Questions This Section Answers

• What measured visibility pattern and review priority does Lemonaid Health have in ED Treatment Pills?

Lemonaid Health recorded 98 mentions (34.88%) and 79 recommendations (28.11%) across 281 answers included in the benchmark. Top 3 placements numbered 28; first-place recommendations numbered 1. Framing among its mentions was 79 positive, 19 neutral and 0 negative.

From October 2026 to November 2026, Lemonaid Health's mention count fell from 108 to 98, while its recommendation count fell from 90 to 79. The recommendation rate was 30.41% and 28.11% respectively.

AI answers contained 0 conflicting claims about Lemonaid Health: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://lemonaidhealth.com/drug/viagra.

Selected third-party review candidate: https://walgreens.com/topic/virtual-healthcare/sexual-health/sildenafil.jsp.

Lemonaid Health is mentioned in roughly a third of answers and recommended in most of them, but first-place finishes are rare. Its recorded counts fell in the later sample, which we note without attributing a cause. We would review the supplied pages for clarity on the treatments offered, verify current details, and brief content aimed at the questions where the brand is already visible.

The CiteWorks five-step improvement plan

Step 1. Establish the baseline

Questions This Section Answers

• What should the agency deliver when it works to establish the baseline for ED Treatment Pills?

We would build a scorecard that records each company's mentions, recommendations and placements alongside the month and answer set they came from. Every entry gets an owner, an evidence requirement and a review status, so later comparisons rest on documented conditions rather than memory. This baseline also notes which companies are in scope, since earlier months measured different sets.

Step 2. Verify disputed facts

Questions This Section Answers

• What should the agency deliver when it works to verify disputed facts for ED Treatment Pills?

AI answers contained 23 conflicting claims across 3 companies. Another 1 possible conflicts were excluded because their company matches were uncertain. The conflicting claims need fact-checking before any corrections are proposed.

The disputed claims logged against three companies need checking before anyone proposes a correction. For each, we would confirm the entity, the date and the primary source, then record whether the claim is confirmed, unresolved or a no-change decision. The uncertain company match stays outside this queue until its identity is settled.

Step 3. Review owned pages

Questions This Section Answers

• What should the agency deliver when it works to review owned pages for ED Treatment Pills?

Each supplied owned-page candidate gets a brief describing what the page should clarify for buyers, grounded in verified facts rather than assumptions about current contents. We would check the live page and primary sources first, then note proposed edits, no-change decisions and open questions separately so the record stays honest about what was actually done.

Step 4. Review third-party sources

Questions This Section Answers

• What should the agency deliver when it works to review third-party sources for ED Treatment Pills?

For the third-party pages, we would confirm what each source currently says before preparing any request. A citation in an answer does not show that the source shaped it, so requests should rest on verified content gaps or inaccuracies. Each package records the evidence, the ask and the response, kept apart from measured answer outcomes.

Step 5. Address buyer questions and measure again

Questions This Section Answers

• What should the agency deliver when it works to address buyer questions and measure again for ED Treatment Pills?

The observed buyer questions give us a starting list for content briefs, not proof of demand. We would draft briefs that answer those questions directly and factually, then measure again on a documented cohort. Completed work is tracked separately from answer results, and we make no claim that publishing will change visibility.

Third-party authority and citation opportunities

Questions This Section Answers

• Which cited publisher pages support targeted source review in ED Treatment Pills?

These pages are candidates for review, not confirmed errors. Citation appearances are counted across the captured answers and are not added again for each company.

The publisher list should be prioritized by how often each page is cited and how many of the client's competitors it covers. Pages cited across many answers and touching several companies are the most efficient places to check first, but each needs its current contents verified before any request is drafted.

We would review the highest-appearance pages for accuracy on the specific claims in dispute, then prepare evidence-backed requests only where a genuine gap or error is confirmed. Citation counts describe how often a page appeared in captured answers, not how much influence it had.

What we'd prioritize first

The first priority is the fact-checking queue, because disputed pricing and trial claims affect buyer decisions and any page work depends on resolving them. Alongside that, we would build the baseline scorecard so future months can be compared on documented terms.

The second priority is page and source review for the companies with the widest reach, where small improvements in clarity reach the most answers. Buyer-question briefs follow once facts are settled. Each stage records completed work separately from measured outcomes, with no promise of visibility gains.

Methodology and conclusion

Questions This Section Answers

• What do the ED Treatment Pills sample and source-review limits allow us to conclude?

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 281 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 800 captured answers and 5650 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

July 2026 measured a different set of companies, so it is excluded from this comparison. August 2026 measured a different set of companies, so it is excluded from this comparison. September 2026 measured a different set of companies, so it is excluded from this comparison.

The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.

This report describes answer visibility for a defined peer set in a single reporting month, using answers that met the benchmark's inclusion rules. Recommendations require both endorsement and positive wording, and placements sit inside recommendations rather than adding to them. The monthly samples differ, so comparisons show what changed, not why.

We would use these results to set a documented baseline, resolve disputed claims against primary sources, and brief page and content work where the evidence supports it. Any later measurement should repeat the same cohort and collection conditions so the comparison is meaningful.